Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series
Ann Rheum Dis
.
2019 Nov;78(11):e123.
doi: 10.1136/annrheumdis-2018-214449.
Epub 2018 Oct 23.
Authors
Javier Narváez
1
,
Judit LLuch
2
,
Juan José Alegre Sancho
3
,
Maria Molina-Molina
4
,
Joan Miquel Nolla
2
,
Ivan Castellví
5
Affiliations
1
Departments of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain fjnarvaez@bellvitgehospital.cat.
2
Departments of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain.
3
Department of Rheumatology, Hospital Universitario Dr. Peset, Valencia, Spain.
4
Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain.
5
Rheumatology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
PMID:
30352892
DOI:
10.1136/annrheumdis-2018-214449
No abstract available
Keywords:
Treatment; pulmonary fibrosis; systemic sclerosis.
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Humans
Lung Diseases, Interstitial*
Scleroderma, Systemic*
Substances
Antibodies, Monoclonal, Humanized
tocilizumab